| Project/Area Number |
04670747
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Saitama Medical School |
|---|
Principal Investigator |
MAEDA Hiroo Saitama Medical School, Faculty of Medicine, Professor, 医学部, 教授 (30134597)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHISHIKURA Yuko Saitama Medical School, Faculty of Medicine, Assistant, 医学部, 助手 (80181105)
MURATA Nobuo Saitama Medical School, Faculty of Medicine, Astt.Prof., 医学部, 講師 (10200297)
TOHYAMA Hiroshi Saitama Medical School, Faculty of Medicine, Professor, 医学部, 教授 (00008278)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1993: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1992: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | Gastrointestinal surgery / Adverse effects of transfusion / Autologous blood transfusion / Erythropoietin |
|---|
| Research Abstract |
To prevent adverse effects of homologous blood transfusion (HBT), we administered recombinant human erythropoietin (EPO) to the patients undergoing gastrointestinal surgery couples with or without autologous blood donation (ABD). We also measured the endogenous EPO in these patients.
1) The EPO level in cancer patients tested was found relatively lower than that in patients with iron deficiency anemia.
2) Daily administration of recombinant EPO (3,000-6000 IU) for 7 days prior operation raised Hb consentration in patients by approximately 1.0 g/dl.
3) Autologous blood deposit (400-600 ml) coupled with adoministration of EPO (3000 IU) also raised Hb concentration increment by 0.8 g/dl, which was essentially same with that of EPO adoministration alone. However, since autologous blood deposit induces medical staffs not to perform HBT and administration of EPO substantially raises Hb concentration, autologous blood donation together with administration of recombinant EPO promises reduction and thereby prevention of adverse effects of HBT.
|
